Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus radiotherapy in recurrent glioblastoma (phase 2, single arm)
ChiCTR2000039701Phase 2Recruiting
- Sponsor
- Tianjin Huanhu Hospital
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in glioblastoma (GBM), sponsored by Tianjin Huanhu Hospital. Primary endpoint: 6-month progression-free survival rate (PFS6). Started Dec 2020; status: recruiting.
02
Drugs
niraparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2000039701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039701.